RxDoctor Payments DataLook up a doctor →

Amanda Stone

Primary Care · Wilmington, NCNPI 1821338252

Payments from drug & device makers

$8,605in general payments, 2019–2025

Across 531 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$884
  • GSK$735
  • AstraZeneca$524
  • Lilly USA, LLC$438
  • Pfizer$410
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,605 in reported general payments places this provider in the 95th percentile of 236 primary care providers in North Carolina.

See all primary care providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,751
Medicare patients
114
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$101,554
JardianceEmpagliflozin45$44,612
LinzessLinaclotide25$23,472
JanuviaSitagliptin Phosphate19$16,758
RybelsusSemaglutide13$13,558
FarxigaDapagliflozin Propanediol12$13,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,967
Soliqua 100-33Insulin Glargine/Lixisenatide14$11,867
XareltoRivaroxaban17$10,383
SymbicortBudesonide/Formoterol Fumarate12$7,028
Wixela InhubFluticasone Propion/Salmeterol15$1,764
Albuterol Sulfate HfaAlbuterol Sulfate67$1,758
Atorvastatin Calcium219$1,502
Omeprazole107$1,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,647$115,11286 claims
Boehringer IngelheimJardiance$313$44,61245 claims
AbbVieLinzess$884$23,47225 claims
AstraZenecaFarxiga, Symbicort$524$20,33224 claims
MerckJanuvia$220$16,75819 claims
GSKTrelegy Ellipta$735$11,96717 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$108$11,86714 claims
Johnson & JohnsonXarelto$175$10,38317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 236 primary care providers in North Carolina.

Other primary care in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →